A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinoma

BackgroundProgrammed cell death ligand 1 (PD-L1) inhibitors have limited efficacy as monotherapy in patients with recurrent/metastatic (R/M) Human Papilloma Virus (HPV) oropharyngeal squamous cell carcinoma (OPSCC). A phase I study of the therapeutic HPV-16 DNA vaccine AMV002 in curatively treated p...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Rahul Ladwa, Janin Chandra, Wai-Ping Woo, Neil Finlayson, Howard Liu, Margaret McGrath, Adrienne See, Brett G. Hughes, Caroline L. Cooper, Jim E. Jackson, Marcin Dzienis, Yan Xu, Benedict Panizza, Ian Frazer, Sandro V. Porceddu
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2024-07-01
Ráidu:	Frontiers in Oncology
Fáttát:	immune checkpoint inhibitor HPV - human papillomavirus HPV vaccination immunotherapies oropharangeal cancer
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1419258/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!